Last reviewed · How we verify
ALXN2080
At a glance
| Generic name | ALXN2080 |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants (PHASE1)
- A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults (PHASE1)
- Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALXN2080 CI brief — competitive landscape report
- ALXN2080 updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI